TopgOptions

ARDS 1250% upside potential according to H.C. Wainwright !!!

看多
NASDAQ:ARDS   None
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."

Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment!

Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."

ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.

It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.

Market Cap of only 21.22Mil

52 Week Range 1.49 - 8.47

You can buy the all time low now!

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。